Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (284)	4/22/1999 4:58:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 3558

REGN had 5 presentations at the Experimental Biology Meeting of the Federation of American Societies of Experimental Biology (FASEB) in Washington, D.C. (www.fasb.org) The first two are posters and the last three are symposia. An abstract is available for the 5th one. Jason ---------------------------- Title/Author/Institute 1 Title: TRANSGENIC OVEREXPRESSION OF VEGF AND ANGIOPOIETIN-1 INDUCE THE PROLIFERATION OF VESSELS OF DIFFERENT SIZE. Authors: K.M. SMITH, G. THURSTON, C. SURI, T.J. MURPHY, G.D. YANCOPOULOS AND D.M. MCDONALD. Inst: UCSF AND REGENERON PHARMACEUT, TARRYTOWN, NY. Session Title:ANGIOGENESIS/MICROVASCULAR REMODELING 2 Title: SKIN MICROVASCULATURE IN MICE THAT TRANSGENICALLY OVEREXPRESS ANGIOPOIETIN-1 IS RESISTANT TO INFLAMMATORY STIMULI. Authors: G. THURSTON, C. SURI, K.M. SMITH, G.D. YANCOPOULOS AND D.M. MCDONALD. Inst: UCSF AND REGENERON PHARMACEUT., TARRYTOWN, NY. Session Title:ANGIOGENESIS/MICROVASCULAR REMODELING 3 Title: ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 INDUCE ANGIOGENESIS IN A FIBRIN-MATRIX MODEL IN VITRO. Authors: K. TEICHERT-KULISZEWSKA, N. JONES, A.I.M. CAMPBELL, S. BABAEI, L.S. ROTH, M.P. BENDECK, K. ALITALO, D.J. DUMONT, G.D. YANCOPOULOS AND D.J. STEWART. Inst: ST. MICHAEL'S HOSP., UNIV. OF TORONTO SUNNYBROOK HLTH. SCI. CTR., UNIV. OF HELSINKI AND REGENERON PHARMACEUT. INC. Session Title:TISSUE REMODELING IN ANGIOGENESIS 4 Title: ANGIOPOIETINS AND VASCULAR DEVELOPMENT. Authors: G.D. YANCOPOULOS. Inst: REGENERON PHARMACEUT. INC. Session Title:VASCULAR DEVELOPMENT AND PATTERNING 5 Title: THE ANGIOPOIETINS: CRITICAL ROLES DURING NORMAL AND PATHOLOGIC ANGIOGENESIS. Authors: G.D. YANCOPOULOS. Inst: REGENERON PHARMACEUT. INC., TARRYTOWN, NY. Session Title:EXTRACELLULAR MATRIX AND SIGNALING --------------------------------- Program Number: 632.1 The Angiopoietins: Critical Roles During Normal and Pathologic Angiogenesis George D. Yancopoulos. Regeneron Pharmaceuticals, Inc. We have recently identified a family of growth factors, the Angiopoietins, that join the members of the vascular endothelial growth factor (VEGF) family as the only known growth factors largely specific for vascular endothelial cells. For both the Angiopoietins and the VEGFs, this specificity is due to the fact that these factors act via a largely endothelial cell-specific family of receptor tyrosine kinases; the receptors bound by the Angiopoietins are known as the TIE receptors. Indicating that tight regulation of the TIE receptors is crucial for normal angiogenesis, the Angiopoietins provide the first example of positive and negative regulators acting on the same receptor tyrosine kinase in vertebrates: Angiopoietin-1 (Ang-1) is a naturally-occurring activator of the TIE receptors, while Angiopoietin-2 (Ang-2) is a naturally-occurring antagonist. Gene knockout studies in mice initially suggested that while VEGF is necessary for early stages of vascular development, Angiopoietin-1 (Ang-1) is required for later stages of vascular remodeling. More recent studies confirm the notion that the Angiopoietins and the VEGFs work together in complementary and coordinated fashion, not only during development but in the initiation of both normal and pathological (e.g. as in tumors) neovascularization states in the adult. Preliminary investigations indicate that the Ang-1 and Ang-2 can be used to positively and negatively regulate blood vessel growth in vivo, suggesting that the Angiopoietins may be exciting candidates to be considered for the therapeutic manipulation of angiogenesis.

To: Miljenko Zuanic who wrote (284)	4/28/1999 7:01:00 AM
From: harkenman	Read Replies (1) \| Respond to of 3558

Warner-Lambert's Chief Says Company Is Open to Acquisitions Any impact to REGN? By ELYSE TANOUYE Staff Reporter of THE WALL STREET JOURNAL PARSIPPANY, N.J -- Warner-Lambert Co. isn't for sale, but it is certainly open to opportunities to acquire other products or companies such as its planned purchase of Agouron Pharmaceuticals Inc., the company's incoming chief executive said. In an interview after Warner-Lambert's annual meeting here, Lodewijk J.R. de Vink said, "We can do it on our own, we've shown it in the past. We aren't hanging the 'for sale' sign on the door. It's not what we want to do." But he added that the company has the wherewithal to make acquisitions. He declined to comment further, citing regulatory restrictions surrounding the company's pending acquisition of Agouron. Warner-Lambert's stock has taken a pounding lately because of concerns that its diabetes drug, Rezulin, can cause liver damage in some patients. Company officials at the meeting stressed that the liver toxicity is very rare, reported so far in 34 patients out of 1.6 million who have taken the drug. Retiring Chairman Melvin Goodes told shareholders that newer diabetes drugs that rival companies are about to introduce into the market have been tested in a few thousand patients only and thus any potential rare side-effects, such as those seen in Rezulin, won't turn up until the drugs are mass marketed. Mr. Goodes said the company plans to conduct head-to-head studies comparing Rezulin's safety and efficacy against the new competitors entering the market. As to the issue of whether Warner-Lambert would agree to be acquired or to merge with another drug company, he said, "no way." He closed the meeting, and his 34-year career at Warner-Lambert, saying "the best days lie ahead" for the company. His retirement will be official Saturday. Mr. de Vink, meanwhile, said the company will try to expand its blockbuster cholesterol drug, Lipitor, to markets around the world. He also said Lipitor's sales are expected to keep growing strongly. Warner-Lambert shares rose $1.50 to $68.375 in New York Stock Exchange composite trading Tuesday.